Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
Grazini U, Markovets A, Ireland L, O'Neill D, Phillips B, Xu M, Pfeifer M, Vaclova T, Martin MJ, Bigot L, Friboulet L, Hartmaier R, Cuomo ME, Barry ST, Smith PD, Floc'h N.
Grazini U, et al. Among authors: smith pd.
Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38630555